News

Investigators looked at data from 3 analyses showed a reduction in mortality was observed across a spectrum of baseline oxygen requirements, at different timeframes, over the course of the pandemic, and in various geographies.

Africa sees third wave as only 1% of the population is fully vaccinated.

The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.

A study paired long-term care facilities (LTCF) staff who were recovered with susceptible residents to help reduce transmission. The goal was simple: pair those susceptible staff and residents with those who were recovered and felt to have protective immunity.

EUAs can enable people to get immediate access to preventive therapy or treatment, but is it always worth aiming for full approval?

Modeling studies highlight best approaches for schools in the coming academic year.

QPX9003 was developed through an NIAID-supported drug discovery collaboration with world experts.

CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity.

Investigators in Brazil attribute Trichosporon asahii fungemia in critically ill COVID-19 patients to “overexposure” to antibiotics and corticosteroids.

A discussion surrounding Novavax’s NVX-CoV2373 with Lisa Dunkle, MD.

Individuals with 3 or more comorbid conditions took longer for a negative SARS-CoV-2 PCR test result.

Multi-system inflammatory syndrome in children (MIS-C), is thought to affect 1 in 50,000 children with SARS-CoV-2 infection.

Social factors associated with viral spread could be useful for pinpointing areas that need public health interventions.

Contact tracing can be an effective tool for identifying new cases of COVID-19, but a new study found that close contacts were reported for only about a third of laboratory confirmed cases.

The SARS-CoV-2 virus was seen to be circulating as early as December of 2019.

Rhinoviruses have been shown to protect against influenza, can they also help with SARS-COV-2?

A balance disruption between pro-clotting and anti-clotting molecules drive the blood clotting.

Regeneron’s monoclonal antibodies, casirivimab and imdevimab (REGEN-COV), reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response.

This mutation also known as B.1.617.2, and first discovered in India is making its way westward and is an emerging infection in the US.

The EKG showed a negative predictive value of 99.2%.

Non-white patients were deemed to be at a greater risk for reinfection.

Heart disease was seen to increase odds of severe disease by nearly four-fold.

Five people in 4 US states in the 20-21 influenza season contracted influenza A virus variants commonly spread among pigs, but without person-to-person spread.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

Pre-existing medical conditions as well as "medical complexity" increase risk for severe COVID-19 illness and hospitalization in children.

Poorly fitting masks can double the risk of infection for the wearer and those around them.

India plans to manufacture over 2 billion doses of COVID-19 vaccines by December